Literature DB >> 31628931

Early treatment with C1 esterase inhibitor improves weight but not memory deficits in a rat model of status epilepticus.

Nicole D Schartz1, Alexandra L Sommer2, Samantha A Colin3, Loyda B Mendez4, Amy L Brewster5.   

Abstract

BACKGROUND: Status epilepticus (SE) is a prolonged and continuous seizure that lasts for at least 5 min. An episode of SE in a healthy system can lead to the development of spontaneous seizures and cognitive deficits which may be accompanied by hippocampal injury and microgliosis. Although the direct mechanisms underlying the SE-induced pathophysiology remain unknown, a candidate mechanism is hyperactivation of the classical complement pathway (C1q-C3 signaling). We recently reported that SE triggered an increase in C1q-C3 signaling in the hippocampus that closely paralleled cognitive decline. Thus, we hypothesized that blocking activation of the classical complement pathway immediately after SE may prevent the development of SE-induced hippocampal-dependent learning and memory deficits.
METHODS: Because C1 esterase inhibitor (C1-INH) negatively regulates activation of the classical complement pathway, we used this drug to test our hypothesis. Two groups of male rats were subjected to 1 hr of SE with pilocarpine (280-300 mg/kg, i.p.), and treated with either C1-INH (SE+C1-INH, 20 U/kg, s.c.) or vehicle (SE+veh) at 4, 24, and 48 h after SE. Control rats were treated with saline. Body weight was recorded for up to 23 days after SE. At two weeks post SE, recognition and spatial memory were determined using Novel Object Recognition (NOR) and Barnes maze (BM), respectively, as well as locomotion and anxiety-like behaviors using Open Field (OF). Histological and biochemical methods were used to measure hippocampal injury including cell death, microgliosis, and inflammation.
RESULTS: One day after SE, both SE groups had a significant loss of body weight compared to controls (p<0.05). By day 14, the weight of SE+C1-INH rats was significantly higher than SE+veh rats (p<0.05), and was not different from controls (p>0.05). At 14 days post-SE, SE+C1-INH rats displayed higher mobility (distance travelled and average speed, p<0.05) and had reduced anxiety-like behaviors (outer duration, p<0.05) than control or SE+veh rats. In NOR, control rats spent significantly more time exploring the novel object vs. the familiar (p<0.05), while rats in both SE groups spent similar amount of time exploring both objects. During days 1-4 of BM training, the escape latency of the control group significantly decreased over time (p<0.05), whereas that of the SE groups did not improve (p>0.05). Compared to vehicle-treated SE rats, SE+C1-INH rats had increased levels of C3 and microglia in the hippocampus, but lower levels of caspase-3 and synaptic markers.
CONCLUSIONS: These findings suggest that acute treatment with C1-INH after SE may have some protective, albeit limited, effects on the physiological recovery of rats' weight and some anxiolytic effects, but does not attenuate SE-induced deficits in hippocampal-dependent learning and memory. Reduced levels of caspase-3 suggest that treatment with C1-INH may protect against cell death, perhaps by regulating inflammatory pathways and promoting phagocytic/clearance pathways.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  C1 esterase inhibitor; C3 complement; Epilepsy; Inflammation; Memory; Microglia; Status epilepticus; Synaptic proteins

Mesh:

Substances:

Year:  2019        PMID: 31628931      PMCID: PMC6879103          DOI: 10.1016/j.physbeh.2019.112705

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  66 in total

Review 1.  Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics.

Authors:  A Sahu; J D Lambris
Journal:  Immunopharmacology       Date:  2000-08

Review 2.  The role of inflammation in epilepsy.

Authors:  Annamaria Vezzani; Jacqueline French; Tamas Bartfai; Tallie Z Baram
Journal:  Nat Rev Neurol       Date:  2010-12-07       Impact factor: 42.937

3.  Knockdown of circulating C1 inhibitor induces neurovascular impairment, glial cell activation, neuroinflammation, and behavioral deficits.

Authors:  Dorit Farfara; Emily Feierman; Allison Richards; Alexey S Revenko; Robert A MacLeod; Erin H Norris; Sidney Strickland
Journal:  Glia       Date:  2019-03-18       Impact factor: 7.452

4.  Comparing patients' and practitioners' views on epilepsy concerns: a call to address memory concerns.

Authors:  James W McAuley; John O Elliott; Sonia Patankar; Sheri Hart; Lucretia Long; J Layne Moore; Bassel F Shneker
Journal:  Epilepsy Behav       Date:  2010-12       Impact factor: 2.937

5.  The powerful neuroprotective action of C1-inhibitor on brain ischemia-reperfusion injury does not require C1q.

Authors:  Maria Grazia De Simoni; Emanuela Rossi; Claudio Storini; Simone Pizzimenti; Cinara Echart; Luigi Bergamaschini
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

6.  A complement-microglial axis drives synapse loss during virus-induced memory impairment.

Authors:  Michael J Vasek; Charise Garber; Denise Dorsey; Douglas M Durrant; Bryan Bollman; Allison Soung; Jinsheng Yu; Carlos Perez-Torres; Arnaud Frouin; Daniel K Wilton; Kristen Funk; Bette K DeMasters; Xiaoping Jiang; James R Bowen; Steven Mennerick; John K Robinson; Joel R Garbow; Kenneth L Tyler; Mehul S Suthar; Robert E Schmidt; Beth Stevens; Robyn S Klein
Journal:  Nature       Date:  2016-06-23       Impact factor: 49.962

Review 7.  Psychiatric comorbidities in epilepsy.

Authors:  W Curt LaFrance; Andres M Kanner; Bruce Hermann
Journal:  Int Rev Neurobiol       Date:  2008       Impact factor: 3.230

8.  C1-inhibitor attenuates neurobehavioral deficits and reduces contusion volume after controlled cortical impact brain injury in mice.

Authors:  Luca Longhi; Carlo Perego; Fabrizio Ortolano; Elisa R Zanier; Paolo Bianchi; Nino Stocchetti; Tracy K McIntosh; Maria Grazia De Simoni
Journal:  Crit Care Med       Date:  2009-02       Impact factor: 7.598

9.  Rapamycin reverses status epilepticus-induced memory deficits and dendritic damage.

Authors:  Amy L Brewster; Joaquin N Lugo; Vinit V Patil; Wai L Lee; Yan Qian; Fabiola Vanegas; Anne E Anderson
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

10.  Rapamycin prevents acute dendritic injury following seizures.

Authors:  Dongjun Guo; Linghui Zeng; Jia Zou; Linglin Chen; Nicholas Rensing; Michael Wong
Journal:  Ann Clin Transl Neurol       Date:  2016-01-19       Impact factor: 4.511

View more
  4 in total

Review 1.  Aberrant Complement System Activation in Neurological Disorders.

Authors:  Karolina Ziabska; Malgorzata Ziemka-Nalecz; Paulina Pawelec; Joanna Sypecka; Teresa Zalewska
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

2.  Suppression of Microgliosis With the Colony-Stimulating Factor 1 Receptor Inhibitor PLX3397 Does Not Attenuate Memory Defects During Epileptogenesis in the Rat.

Authors:  Season K Wyatt-Johnson; Alexandra L Sommer; Kevin Y Shim; Amy L Brewster
Journal:  Front Neurol       Date:  2021-06-03       Impact factor: 4.003

3.  Astrocytic BDNF and TrkB regulate severity and neuronal activity in mouse models of temporal lobe epilepsy.

Authors:  Sara Fernández-García; Anna Sancho-Balsells; Sophie Longueville; Denis Hervé; Agnès Gruart; José María Delgado-García; Jordi Alberch; Albert Giralt
Journal:  Cell Death Dis       Date:  2020-06-01       Impact factor: 8.469

4.  Acyl-CoA synthetase 6 is required for brain docosahexaenoic acid retention and neuroprotection during aging.

Authors:  Regina F Fernandez; Andrea S Pereyra; Victoria Diaz; Emily S Wilson; Karen A Litwa; Jonatan Martínez-Gardeazabal; Shelley N Jackson; J Thomas Brenna; Brian P Hermann; Jeffrey B Eells; Jessica M Ellis
Journal:  JCI Insight       Date:  2021-06-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.